Article
FDA's Fast Track Designation Granted to Allogeneic CAR Therapy for B-cell Pre
Rating:
0.0
Views:
75
Likes:
1
Library:
1
The FDA has granted a fast track designation to PBCAR0191, a CD19-directed allogeneic chimeric antigen receptor T-cell therapy, for the treatment of patients with advanced B-cell precursor acute lymphoblastic leukemia.
Rate This Post
Rate The Educational Value
Rate The Ease of Understanding and Presentation
Interesting or Boring? Rate the Entertainment Value